By Innovation4Alpha
4
44 ratings
The podcast currently has 13 episodes available.
One of the most creative, insightful and articulate startup leaders in the industry, Matan Magril is always fascinating to talk with. At 22, he launched the full-scale event production and branding agency, Imperial Entertainment, which he successfully exited at 25 to join the founding team of Advocacy Asia, China’s first word-of-mouth platform.
Matan is the Founder of FoodieTrip, the NYC-based marketing spearheads peer-to-peer marketplace that connects travelers to local food guides for authentic gastronomic experiences around the world. JetPack is the culmination of Matan’s decade-worth of experience founding and growing companies, as well as his passion for overhauling traditional capital raising.
Through JetPack, Matan is able to provide uniquely exceptional startups with the guidance and support he sought when building his own ventures.
Matan holds a B.A. in Finance from the University of Florida and Universita Bocconi in Milan.
Dr. Gupta is very active working with innovative startups across medical device and digital health and serves as a Sr. Clinical Advisor with AngelMD and as a member of the AngelMD Clinical Advisory Board. He specializes in hip arthroscopy and sports medicine at the Nova Orthopedic & Spine Care division of The Centers in Woodbridge, Virginia. Dr. Gupta has gained hands-on experience in the sports medicine field through his fellowship with New York University Hospital for Joint Disease and his time with the New York Rangers, Chicago Sky and UIC Flames athletic program. In addition to his interest in sports medicine, Dr. Gupta specializes in hip arthroscopy and robotic assisted minimally-invasive total hip arthroplasty. In his spare time, Dr. Gupta enjoys staying active through soccer, tennis, running, biking and hiking.
Hall Venture Partners is the venture fund sponsored by and investing alongside the Hall Family. The Halls are a 3rd generation family office that operates a massive incubation campus in Provo, UT called Hall Labs.
Web site: www.hallvp.com
Opportunity Zone talk: https://youtu.be/S8kqhrzn48Q
30 second video overview: https://vimeo.com/596778849/07635d0bfd
Embrace Prevention Care provides Personal Prevention Care to older adults with heart failure and other chronic conditions to help them take healthy actions that reduce preventable hospital stays. They partner with physicians to extend their reach into the home to help patients follow their prevention plans and drug regimens to achieve the goals that matter most to the patient while reducing the cost of care. Embrace is the first to combine the tele-health care of local nurse practitioners with a geriatric pharmacy in their Prevention Care Platform to provide expert personalized geriatric preventive care to allow older adults to stay healthy, independent and age in place.
AngelMD Profile: https://www.angelmd.co/en/startups/embrace-prevention-care
Yuri is a forward-thinking entrepreneur and thought leader who has a true passion for community and global impact projects. He has served in a wide range of business and technical capacities across varied industries and nonprofits. He has a desire for developing and leading teams, strategic initiatives, streamlining key business processes, as well as creating innovative products, services, business models and platforms.
Yuri has 20+ years of Management and Technology leadership experience. Working with leading-edge Hardware, Software as a Service and IoT technology companies. He especially enjoys working with organizations looking to employ the next generation of Digital Transformation Strategies.
Previous to his career in technology, Yuri served as a Firefighter/EMT for 7 years and in the United States Army for 9 years.
Geoffrey Colby, MD, PhD is a neurosurgeon and expert specialist in the open microsurgical and minimally-invasive endovascular treatment of cerebrovascular disorders of the brain and spine. He is the Director of Cerebrovascular Neurosurgery and an Associate Professor of Neurosurgery and Radiology at UCLA. Dr. Colby is also the Director of the Neurosurgery Residency training Program at UCLA and Chair of the AngelMD Clinical Advisory Board Department of Neurosurgery.
Dr. Colby is a world-class expert using flow diversion for treatment and cure of brain aneurysms. He is the only neurosurgeon on the West Coast certified to train and proctor physicians on the use of all FDA-approved flow diverting stents and intravascular devices for treatment of brain aneurysms. He is sought after to assist other specialists and provide guidance on complex aneurysm procedures across the country and internationally. He also performs embolization for subdural hematoma (SDH) and tumors of the brain and spine.
Dr. Colby’s research explores technical advances to improve patient outcomes and the development of novel devices to treat cerebrovascular disorders. He has co-authored more than 100 peer-reviewed scientific articles and book chapters, and he has served as the principal investigator for many clinical studies testing new endovascular devices to treat cerebral aneurysms and stroke. He has lectured around the world on 4 continents, and he is a reviewer for the main scientific journals in the field of cerebrovascular disorders.
Dr. Colby joined UCLA in 2017 from The Johns Hopkins University School of Medicine in Baltimore, where he was an Assistant Professor of Neurosurgery, Neurology and Radiology. During his tenure there, he performed thousands of neurosurgical procedures and was an avid researcher. His passion for teaching earned him the Department of Neurosurgery Chairman’s Award of Excellence, and the Neurosurgery house staff at Johns Hopkins presented him with the Richard J. Otenasek, Jr. Faculty Teaching Award. While at UCLA, he has been awarded similar honors for excellence in teaching and education, receiving the Ulrich Batzdorf, MD Gold Teaching Award.
Dr. Colby received his MD and PhD degrees from Columbia University in New York City. He completed his internship and neurosurgery residency at The Johns Hopkins Hospital, as well as a two-year fellowship in endovascular neurosurgery and interventional neuroradiology. He joined the Johns Hopkins faculty in 2013.
He is an avid outdoor enthusiast and has participated in triathlons, marathons, and mountaineering expeditions. He also enjoys casual jogs, bike riding, and hiking.
Matt Patsky is CEO and Lead Portfolio Manager of the Trillium ESG Global Equity strategy and Portfolio Manager of the Trillium Sustainable Opportunities strategy. Matt has over three decades of experience in investment research and investment management. He began his career at Lehman Brothers in 1984 as a technology analyst. In 1989, while covering emerging growth companies for Lehman, he began to incorporate environmental, social, and governance factors into his research, becoming the first sell side analyst in the United States to publish on the topic of socially responsible investing in 1994. As Director of Equity Research for Adams, Harkness & Hill, he built the firm’s powerful research capabilities in socially and environmentally responsible areas such as renewable energy, resource optimization, and organic and natural products. Before Trillium, Matt worked at Winslow Management Company in Boston, where he served as director of research, chairman of the investment committee, and portfolio manager for the Green Growth and Green Solutions Strategies.
Matt currently serves on the board of TONIIC and has previously served on the Boards of Environmental League of Massachusetts, Shared Interest, Pro Mujer, US SIF, and Root Capital. He is also a member of the Social Venture Circle (SVC) and is a member of the CFA Society Boston and is a Chartered Financial Analyst charterholder.
Trillium Asset Management is at the forefront of thought leadership and continues to draw from decades of experience focused exclusively on responsible investing. Trillium’s founder, Joan Bavaria, was a true visionary and served as an early catalyst for change in the investment industry. The firm’s innovative approach led to the creation of numerous organizations, the development of the ESG investment field, and the first generation of investors focused on improved environmental, social, and governance outcomes.
Today, the firm is an impact-driven, ESG-focused firm dedicated to aligning values with investment objectives. Trillium’s commitment to active ownership and shareholder advocacy has contributed to concrete and positive change.
Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent mucosal infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. They are unlocking the full therapeutic value of human milk antibodies to create the next-generation of anti-infectives that can battle even the world’s most dangerous pathogens including Covid. Lactiga has earned multiple awards, media attention (Globe & Mail, CTV, Toronto Star) and is participating in the On Deck Health (ODH2) cohort.
AngelMD Profile: https://www.angelmd.co/en/startups/lactiga
Julie Anderson is the Director of Strategic Initiatives at Cambia Grove and a healthcare veteran.
Cambia Grove is a health care innovation hub focused on bridging the gap between entrepreneurs and the traditional health care sectors.
Formed by a large payor, the organization sits in an interesting spot to help startups navigate some of the complexities of healthcare, reimbursements and more.
Cambia Grove Goals:
www.cambiagrove.com
https://www.cambiagrove.com/programs-and-initiatives/trails-competition
https://www.cambiagrove.com/cambia-grove-membership
Elims is a social impact company that combines seriously effective oral care + real sustainability. They believe you don't have to compromise your health for the planet. That's why Elims is not just sustainable. Each of their products are crafted by dentists, biotech professionals and sustainability experts, and they actually work at keeping your teeth clean and sparkling white. They combine the best of science + nature by only using clinically backed and tested ingredients to effective natural ones to bring your oral care for everyone.
https://www.angelmd.co/en/startups/elims
The podcast currently has 13 episodes available.